CIC
STOK icon

Chase Investment Counsel’s Stoke Therapeutics STOK Stock Holding History

Chase Investment Counsel’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,738
Closed -$280K – 139
2024
Q2 		$280K Hold
20,738
– – 0.1% 116
2024
Q1 		$279K Buy
+20,738
New +$126K 0.1% 124

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chase Investment Counsel's STOK Position: Q3 2024 in Review

Chase Investment Counsel sold out of Stoke Therapeutics (STOK) in Q3 2024, closing a stake of 20,738 shares — an estimated $280K sold.

Chase Investment Counsel first reported a position in STOK in Q1 2024 and held it in 2 quarters. The position peaked at $280K in Q2 2024. 118 funds tracked by Wall St. Rank hold STOK as of Q3 2024.

  • Chase Investment Counsel reported no remaining Stoke Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Chase Investment Counsel sold 20,738 Stoke Therapeutics shares in Q3 2024, an estimated $280K.
  • Chase Investment Counsel first reported a position in Stoke Therapeutics in Q1 2024 and held it in 2 quarters.
  • Chase Investment Counsel's Stoke Therapeutics position peaked at $280K in Q2 2024.
  • 118 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2024.

Based on Chase Investment Counsel's 13F filing for Q3 2024, filed 5 Nov 2024.